Advances in methods and algorithms in a modern quantum chemistry program package
…, EI Proynov, PA Pieniazek, YM Rhee… - Physical Chemistry …, 2006 - pubs.rsc.org
Advances in theory and algorithms for electronic structure calculations must be incorporated
into program packages to enable them to become routinely used by the broader chemical …
into program packages to enable them to become routinely used by the broader chemical …
Mesenteric venous thrombosis: still a lethal disease in the 1990s
RY Rhee, P Gloviczki, CT Mendonca… - Journal of vascular …, 1994 - Elsevier
Purpose: This study was designed to evaluate progress in diagnosis, management, and clinical
outcome of mesenteric venous thrombosis (MVT). Methods: We retrospectively reviewed …
outcome of mesenteric venous thrombosis (MVT). Methods: We retrospectively reviewed …
Update on neuroblastoma
…, TB Lautz, DS Rhee, MR Langham Jr… - Journal of pediatric …, 2019 - Elsevier
Neuroblastoma is an embryonic cancer arising from neural crest stem cells. This cancer is
the most common malignancy in infants and the most common extracranial solid tumor in …
the most common malignancy in infants and the most common extracranial solid tumor in …
Clinical practice simulation for blood transfusion reactions: an interprofessional approach
JR Rhees, CH Scheese, D Ward… - American Society for …, 2015 - clsjournal.ascls.org
When an acute blood transfusion reaction occurs, clear communication, teamwork, and
knowledge of the roles and responsibilities of each member of the healthcare team are essential. …
knowledge of the roles and responsibilities of each member of the healthcare team are essential. …
Advances in molecular quantum chemistry contained in the Q-Chem 4 program package
A summary of the technical advances that are incorporated in the fourth major release of the
Q-Chem quantum chemistry program is provided, covering approximately the last seven …
Q-Chem quantum chemistry program is provided, covering approximately the last seven …
The molecular classification of multiple myeloma
…, K Hollmig, M Pineda-Roman, G Tricot, F Van Rhee… - Blood, 2006 - ashpublications.org
To better define the molecular basis of multiple myeloma (MM), we performed unsupervised
hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 …
hierarchic clustering of mRNA expression profiles in CD138-enriched plasma cells from 414 …
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
…, A Mohiuddin, M Pineda-Roman, G Tricot, F Van Rhee… - Blood, 2007 - ashpublications.org
To molecularly define high-risk disease, we performed microarray analysis on tumor cells
from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate …
from 532 newly diagnosed patients with multiple myeloma (MM) treated on 2 separate …
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial
…, R Ow, D Polyakov, D Radeanu, CS Rhee… - The Lancet …, 2021 - thelancet.com
Background Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the
general population, and long-term use of systemic corticosteroids is associated with adverse …
general population, and long-term use of systemic corticosteroids is associated with adverse …
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
…, C Morris, F Muwalla, F van Rhee… - Blood, The Journal …, 2002 - ashpublications.org
Bone marrow plasma cells (PCs) from 74 patients with newly diagnosed multiple myeloma (MM),
5 with monoclonal gammopathy of undetermined significance (MGUS), and 31 healthy …
5 with monoclonal gammopathy of undetermined significance (MGUS), and 31 healthy …
CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma
…, JD Shaughnessy Jr, B Barlogie, F van Rhee… - Clinical Cancer …, 2008 - AACR
Purpose: We generated a humanized antibody, HuLuc63, which specifically targets CS1 (CCND3
subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously associated …
subset 1, CRACC, and SLAMF7), a cell surface glycoprotein not previously associated …